{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:53:05Z","timestamp":1758293585153,"version":"3.44.0"},"reference-count":41,"publisher":"Endocrinology Research Centre","issue":"4","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p><jats:bold>BACKGROUND: <\/jats:bold>Combined treatment of differentiated thyroid cancer (DTC) may have an impact on the reproductive health of patients, in particular on the ovarian reserve (OR) of childbearing-age women. However, knowledge in this area is still insufficient to create general recommendations and an algorithm for managing this cohort of patients based on their current reproductive status and desire to realize their reproductive potential.<\/jats:p><jats:p><jats:bold>AIM: <\/jats:bold>To assess ovarian function and OR using anti-M\u00fcllerian hormone (AMH) and follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) in dynamics in the early follicular phase in women of reproductive age receiving combined treatment for DTC.<\/jats:p><jats:p><jats:bold>MATERIALS<\/jats:bold><jats:bold> <\/jats:bold><jats:bold>AND<\/jats:bold><jats:bold> <\/jats:bold><jats:bold>METHODS:<\/jats:bold><jats:bold> <\/jats:bold>In a single-center prospective non-comparative study, the clinical and morphological, anamnestic and laboratory parameters of patients receiving combined treatment for DTC were analyzed. The levels of AMH, FSH, LH and E2 were determined in dynamics \u2013 after surgical treatment but no later than one month before radioiodine therapy (RAIT), as well as 3 and 6 months after RAIT on the background of suppressive therapy.<\/jats:p><jats:p><jats:bold>RESULTS: <\/jats:bold>A total of 39 women aged 18 to 40 years with a median age of 32 years [27; 37] undergoing combined treatment for DTC were enrolled in the study. The frequency of transient menstrual cycle disturbances after surgery was 18%, and after RAIT \u2014 38%. According to the post-operative DTC status the majority of patients belonged to ATA intermediate-risk group (69%). In addition, 72% of patients received thyroid hormone withdrawal for a period of 4 weeks as a preparation for RAIT. The average activity of 131I was 3720 MBq [3050; 3838]. The levels of FSH and LH did not differ significantly before and after RAIT (R=NS). The level of E2 decreased significantly 3 months after RAIT (P&lt;0.010), further increasing in 6 months to almost the initial values (P=NS). The level of AMH decreased significantly 3 and 6 months after RAIT compared with baseline values (P&lt;0.001). The median AMH before the treatment was 4.10 ng\/ml [2.34; 5.82], the nadir of AMH was observed after 3 months \u2014 2.09 ng\/ml [1.05; 3.05], and after 6 months AMH increased to 2.31 ng\/ml [1.42; 3.37]. In 29% of patients, the AMH level decreased below the reference after 3 months. The predictor of AMH level below 1.2 ng\/ml (reflecting reduced OR) 3 months after RAIT was the patient\u2019s age before RAIT. Using the Juden index, a cut-off point of 31 years was determined.<\/jats:p><jats:p><jats:bold>CONCLUSION: <\/jats:bold>The level of AMH decreases significantly after RAIT for DTC, which indicates the effect of the therapy on OR, while age at the time of RAIT is the main predictor of AMH level below 1.2 ng\/ml after 3 months.<\/jats:p>","DOI":"10.14341\/probl13592","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:23:44Z","timestamp":1758201824000},"page":"83-94","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Female reproductive function \u00adafter radioiodine therapy for differentiated thyroid carcinoma"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-1126","authenticated-orcid":true,"given":"M. O.","family":"Korchagina","sequence":"first","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-0020","authenticated-orcid":true,"given":"E. N.","family":"Andreeva","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre;\r\nRussian University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6935-3187","authenticated-orcid":true,"given":"A. R.","family":"Elfimova","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-0335","authenticated-orcid":true,"given":"M. S.","family":"Sheremeta","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7877","authenticated-orcid":true,"given":"G. A.","family":"Melnichenko","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Shobab L, Burman KD, Wartofsky L. Sex Differences in Differentiated Thyroid Cancer. Thyroid. 2022;32(3):224-235. doi: https:\/\/doi.org\/10.1089\/thy.2021.0361","DOI":"10.1089\/thy.2021.0361"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Raymond P, Klein M, Borson-Chazot F. Summary and update on the management of differentiated thyroid cancer in 2023. Ann Endocrinol (Paris). 2024;85(2):110-117. doi: https:\/\/doi.org\/10.1016\/j.ando.2023.11.007","DOI":"10.1016\/j.ando.2023.11.007"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17(3):176-188. doi: https:\/\/doi.org\/10.1038\/s41574-020-00448-z","DOI":"10.1038\/s41574-020-00448-z"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Forrer F, Fischer GF, Maas O, et al. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy. Oncology. 2022;100(2):74-81. doi: https:\/\/doi.org\/10.1159\/000520938","DOI":"10.1159\/000520938"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Nik Hazlina NH, Norhayati MN, Shaiful Bahari I, Nik Muhammad Arif NA. Worldwide prevalence, risk factors and psychological impact of infertility among women: a systematic review and meta-analysis. BMJ Open. 2022;12(3):e057132. doi: https:\/\/doi.org\/10.1136\/bmjopen-2021-057132","DOI":"10.1136\/bmjopen-2021-057132"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Moolhuijsen LME, Visser JA. Anti-M\u00fcllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020;105(11):3361-3373. doi: https:\/\/doi.org\/10.1210\/clinem\/dgaa513","DOI":"10.1210\/clinem\/dgaa513"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cedars MI. Evaluation of Female Fertility-AMH and Ovarian Reserve Testing. J Clin Endocrinol Metab. 2022;107(6):1510-1519. doi: https:\/\/doi.org\/10.1210\/clinem\/dgac039","DOI":"10.1210\/clinem\/dgac039"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772. doi: https:\/\/doi.org\/10.1371\/journal.pone.0008772","DOI":"10.1371\/journal.pone.0008772"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Russell N, Gilmore A, Roudebush WE. Clinical Utilities of Anti-M\u00fcllerian Hormone. J Clin Med. 2022;11(23):7209. doi: https:\/\/doi.org\/10.3390\/jcm11237209","DOI":"10.3390\/jcm11237209"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Peign\u00e9 M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014;12:26. doi: https:\/\/doi.org\/10.1186\/1477-7827-12-26","DOI":"10.1186\/1477-7827-12-26"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Bala J, Seth S, Dhankhar R, et al. Chemotherapy: Impact on Anti-M\u00fcllerian Hormone Levels in Breast Carcinoma. J Clin Diagn Res. 2016;10(2):BC19-BC21. doi: https:\/\/doi.org\/10.7860\/JCDR\/2016\/15933.7328","DOI":"10.7860\/JCDR\/2016\/15933.7328"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Anagnostis P, Florou P, Bosdou JK, et al. Decline in anti-M\u00fcllerian hormone concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: A systematic review and meta-analysis. Maturitas. 2021;148:40-45. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2021.04.002","DOI":"10.1016\/j.maturitas.2021.04.002"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Poseidon Group (Patient-Oriented Strategies Encompassing Individualize D Oocyte Number), Alviggi C, Andersen CY, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452-1453. doi: https:\/\/doi.org\/10.1016\/j.fertnstert.2016.02.005","DOI":"10.1016\/j.fertnstert.2016.02.005"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tal R, Seifer DB, Tal R, et al. AMH Highly Correlates With Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. J Clin Endocrinol Metab. 2021;106(9):2754-2766. doi: https:\/\/doi.org\/10.1210\/clinem\/dgab168","DOI":"10.1210\/clinem\/dgab168"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bel\u2019tsevich DG, Mudunov AM, Vanushko VE, et al. Differentiated thyroid cancer \/\/ Journal of Modern Oncology. 2020;22(4):30-44. (in Russ.) doi: https:\/\/doi.org\/10.26442\/18151434.2020.4.200507","DOI":"10.26442\/18151434.2020.4.200507"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi: https:\/\/doi.org\/10.1089\/thy.2015.0020","DOI":"10.1089\/thy.2015.0020"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Tuttle RM, Ahuja S, Avram AM, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461-470. doi: https:\/\/doi.org\/10.1089\/thy.2018.0597","DOI":"10.1089\/thy.2018.0597"},{"key":"ref18","unstructured":"Adamyan LV, Andreeva EN, Artymuk NV, et al. Federal\u2019nye klinicheskie re-komendacii Rossijjskojj associacii akusherov-ginekologov \u00abAnomal\u2019nye ma-tochnye krovotechenija\u00bb, 2021. (in Russ.)"},{"key":"ref19","unstructured":"Adamyan LV, Andreeva EN, Artymuk NV, et al. Federal\u2019nye klinicheskie re-komendacii Rossijjskojj associacii akusherov-ginekologov \u00abAmenoreja i oligomenoreja\u00bb, 2021. (in Russ.)"},{"key":"ref20","unstructured":"Korsak VS, Dolgushina NV, Korneeva IE, et al. Federal\u2019nye klinicheskie re-komendacii Rossijjskojj associacii akusherov-ginekologov i OOO \u00abRossijj-skaja associacija reprodukcii cheloveka\u00bb \u00abZhenskoe besplodie\u00bb, 2021 (in Russ.)"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702-755. doi: https:\/\/doi.org\/10.1210\/er.2009-0041","DOI":"10.1210\/er.2009-0041"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1277-1287. doi: https:\/\/doi.org\/10.6004\/jnccn.2010.0094","DOI":"10.6004\/jnccn.2010.0094"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review. Cancer Treat Rev. 2015;41(10):925-934. doi: https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.001","DOI":"10.1016\/j.ctrv.2015.09.001"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi: https:\/\/doi.org\/10.1089\/thy.2015.0020.","DOI":"10.1089\/thy.2015.0020"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Sheremeta MS, Trukhin AA, Korchagina MO. The use of radioactive substances in medicine \u2014 history and development prospects. Problems of Endocrinology. 2021;67(6):59-67. (In Russ.) doi: https:\/\/doi.org\/10.14341\/probl12824","DOI":"10.14341\/probl12824"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"TRUNNELL JB, MARINELLI LD. The treatment of metastatic thyroid cancer with radioactive iodine; credits and debits. J Clin Endocrinol Metab. 1949;9(11):. doi: https:\/\/doi.org\/10.1210\/jcem-9-11-1138","DOI":"10.1210\/jcem-9-11-1138"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"DOBYNS BM, MALOOF F. The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. J Clin Endocrinol Metab. 1951;11(11):1323-1360. doi: https:\/\/doi.org\/10.1210\/jcem-11-11-1323","DOI":"10.1210\/jcem-11-11-1323"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989;69(1):186-190. doi: https:\/\/doi.org\/10.1210\/jcem-69-1-186","DOI":"10.1210\/jcem-69-1-186"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20(1):124-140. doi: https:\/\/doi.org\/10.1093\/humupd\/dmt037","DOI":"10.1093\/humupd\/dmt037"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ac\u0131bucu F, Ac\u0131bucu DO, Akkar \u00d6B, et al. Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment. Exp Clin Endocrinol Diabetes. 2016;124(10):593-596. doi: https:\/\/doi.org\/10.1055\/s-0042-115639","DOI":"10.1055\/s-0042-115639"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Yaish I, Azem F, Gutfeld O, et al. A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study. Thyroid. 2018;28(4):522-527. doi: https:\/\/doi.org\/10.1089\/thy.2017.0442","DOI":"10.1089\/thy.2017.0442"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Evranos B, Faki S, Polat SB, et al. Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study. Thyroid. 2018;28(12):1702-1707. doi: https:\/\/doi.org\/10.1089\/thy.2018.0129","DOI":"10.1089\/thy.2018.0129"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"van Velsen EFS, Visser WE, van den Berg SAA, et al. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer. Thyroid. 2020;30(4):580-587. doi: https:\/\/doi.org\/10.1089\/thy.2019.0504","DOI":"10.1089\/thy.2019.0504"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Adamska A, Tomczuk-Bobik P, Pop\u0142awska-Kita AB, et al. Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine. Endocr Connect. 2021;10(10):1283-1290. doi: https:\/\/doi.org\/10.1530\/EC-21-0187","DOI":"10.1530\/EC-21-0187"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Melado Vidales L, Fern\u00e1ndez-Nistal A, Mart\u00ednez Fern\u00e1ndez V, et al. Anti-M\u00fcllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation. Minerva Ginecol. 2017;69(3):225-232. doi: https:\/\/doi.org\/10.23736\/S0026-4784.16.03958-7","DOI":"10.23736\/S0026-4784.16.03958-7"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Borges E, Braga D, Setti A et al. The predictive value of serum concentrations of anti-Mullerian hormone for oocyte quality, fertilization, and implantation. JBRA Assist Reprod 2017;21:176\u201382","DOI":"10.5935\/1518-0557.20170035"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tehrani FR, Firouzi F, Behboudi-Gandevani S. Investigating the Clinical Utility of the Anti-Mullerian Hormone Testing for the Prediction of Age at Menopause and Assessment of Functional Ovarian Reserve: A Practical Approach and Recent Updates. Aging Dis. 2022;13(2):458-467. doi: https:\/\/doi.org\/10.14336\/AD.2021.0825","DOI":"10.14336\/AD.2021.0825"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Nelson SM, Davis SR, Kalantaridou S, et al. Anti-M\u00fcllerian hormone for the diagnosis and prediction of menopause: a systematic review. Hum Reprod Update. 2023;29(3):327-346. doi: https:\/\/doi.org\/10.1093\/humupd\/dmac045","DOI":"10.1093\/humupd\/dmac045"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Weenen C, Laven JSE, Von Bergh ARM, et al. Anti-M\u00fcllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004,10:77-83. doi: https:\/\/doi.org\/10.1093\/molehr\/gah015","DOI":"10.1093\/molehr\/gah015"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Hansen KR, Hodnett GM, Knowlton N, et al. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170-175. doi: https:\/\/doi.org\/10.1016\/j.fertnstert.2010.04.006","DOI":"10.1016\/j.fertnstert.2010.04.006"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Liu T, Zhang W, Xiao S, et al. Mindfulness-based stress reduction in patients with differentiated thyroid cancer receiving radioactive iodine therapy: a randomized controlled trial. Cancer Manag Res. 2019;11:467-474. doi: https:\/\/doi.org\/10.2147\/CMAR.S183299","DOI":"10.2147\/CMAR.S183299"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13592\/10894","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:24:17Z","timestamp":1758201857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,14]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13592","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2025,9,14]]}}}